ZymoGenetics Announces Completion of Enrollment in Phase 2b

[Guest guest]

Aug. 25, 2010, 6:00 a.m. EDT · Recommend · Post:

ZymoGenetics Announces Completion of Enrollment in Phase 2b Clinical Trial with

PEG-Interferon lambda in Hepatitis C

SEATTLE, Aug 25, 2010 (BUSINESS WIRE) -- ZymoGenetics, Inc.

/quotes/comstock/15*!zgen/quotes/nls/zgen (ZGEN 5.08, +0.04, +0.79%) today

announced enrollment has been completed in the Phase 2b clinical trial with

PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV)

infection. ZymoGenetics is investigating PEG-Interferon lambda in collaboration

with Bristol-Myers Squibb Company /quotes/comstock/13*!bmy/quotes/nls/bmy (BMY

26.06, -0.02, -0.08%) for the treatment of HCV infection.

More at

http://www.marketwatch.com/story/zymogenetics-announces-completion-of-enrollment\

-in-phase-2b-clinical-trial-with-peg-interferon-lambda-in-hepatitis-c-2010-08-25\

?reflink=MW_news_stmp